Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 20/20 | 1.00 |
| ▸ | PSEN2 | P49810 | 20/20 | 1.00 |
| ▸ | APH1B | Q8WW43 | 20/20 | 1.00 |
| ▸ | NCSTN | Q92542 | 20/20 | 1.00 |
| ▸ | APH1A | Q96BI3 | 20/20 | 1.00 |
| ▸ | PSENEN | Q9NZ42 | 20/20 | 1.00 |
| ▸ | APP | P05067 | 1/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.67 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13676473 | 1.00 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2783966 | 0.89 | PSEN1 (0.80) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4822276 | 0.88 | PSEN1 (0.86) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8259743 | 0.88 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13676465 | 0.88 | PSEN1 (0.78) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8257620 | 0.88 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL2766736 | 0.88 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1246752 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1081833 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1081832 | 0.87 | PSEN1 (0.77) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551799-B1 | CYCLOHEXYL SULPHONES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20090215775-A1 | Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer | MERCK SHARP & DOHME LTD. (GB) | 2009-08-27 | — | — | US | disclosed |
| EP-1888051-A2 | SULPHONAMIDO-SUBSTITUTED CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LTD. (GB) | 2008-02-20 | — | — | EP | disclosed |
| EP-1551797-B1 | CYCLOHEXYL SULPHONE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006123184-A2 | SULPHONAMIDO-SUBSTITUTED CYCLOHEXYL SULPHONES FOR TREATMENT OF CANCER | MERCK SHARP & DOHME LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
| US-7101895-B2 | Cyclohexyl sulphone derivatives as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-09-05 | — | — | US | disclosed |
| EP-1551799-A1 | CYCLOHEXYL SULPHONES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2005-07-13 | — | — | EP | disclosed |
| US-6890956-B2 | Cyclohexyl sulphones as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2005-05-10 | — | — | US | disclosed |
| US-20040122050-A1 | Cyclohexyl sulphone derivatives as gamma-secretase inhibitors | MERCK SHARP & DOHME LTD. (GB) | 2004-06-24 | — | — | US | disclosed |
| US-20040121995-A1 | Cyclohexyl sulphones as gamma-secretase inhibitors | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2004-06-24 | — | — | US | disclosed |
| WO-2004031139-A1 | CYCLOHEXYL SULPHONES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122050-A1 | Cyclohexyl sulphone derivatives as gamma-secretase inhibitors | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 6/4885APH1B 8/4885 |
| US-20040121995-A1 | Cyclohexyl sulphones as gamma-secretase inhibitors | BACE1, BACE2, APP | PSEN1 4/4885PSEN2 5/4885APH1B 9/4885 |
| US-20090215775-A1 | Sulphonamido-Substituted Cyclohexyl Sulphones for Treatment of Cancer | SDHA, SDHB, TP53 | PSEN1 2352/4885PSEN2 2663/4885APH1B 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.